Purpose: To investigate the safety and efficacy of drug-coated balloons (DCB) for the treatment of femoropopliteal or infrapopliteal lesions in patients with chronic limb-threatening ischemia (CLTI). Materials and Methods: A systematic literature search was conducted in PubMed, Scopus, and Cochrane Central up to January 2020 to identify randomized trials and observational studies presenting data on the effectiveness and safety of DCBs in the treatment of femoropopliteal or infrapopliteal lesions. A meta-analysis utilizing random effects modeling was conducted to investigate primary patency and all-cause mortality at 12 months; the results are reported as the odds ratios (ORs) and 95% confidence intervals (CIs). Secondary outcomes were procedural success, bailout stenting, target lesion revascularization (TLR), reocclusion, major amputation, wound healing, and major adverse limb events. Results: Twenty-six studies, 12 retrospective and 14 prospective, comprising 2108 CLTI patients treated with DCBs for femoropopliteal (n=1315) or infrapopliteal (n=793) lesions were analyzed. The average lesion lengths were 121±44 and 135±53 mm, respectively. The overall 12-month all-cause mortality and major amputation rates were 9% (95% CI 6% to 13%) and 5% (95% CI 2% to 8%), respectively. Primary patency rates were 82% (95% CI 76% to 87%) and 64% (95% CI 58% to 70%), respectively. A sensitivity analysis of the infrapopliteal lesions demonstrated no difference between DCB and balloon angioplasty in terms of primary patency, TLR, major amputation, or mortality over 12 months. However, patients with infrapopliteal lesions undergoing DCB angioplasty did have a significantly lower risk for reocclusion (10% vs 25%; OR 0.38, 95% CI 0.21 to 0.70, p=0.002). Conclusion: DCB angioplasty of femoropopliteal and infrapopliteal lesions in patients with CLTI results in acceptable 12-month patency rates, although comparative data have not shown a patency benefit for infrapopliteal lesions. The 12-month mortality rate of DCB vs balloon angioplasty was not significantly different, but studies with longer-term outcomes are necessary to determine any association between DCB use and mortality in patients with CLTI.
DuffSMafiliosMSBhounsulePHasegawaJT.The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag. 2019;15:187–208.
2.
DuaALeeCJ.Epidemiology of peripheral arterial disease and critical limb ischemia. Tech Vasc Interv Radiol. 2016;19:91–95.
3.
FowkesFGRudanDRudanI, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–1340.
4.
SaraidaridisJTErgulEPatelVI, et al. The Society for Vascular Surgery’s objective performance goals for lower extremity revascularization are not generalizable to many open surgical bypass patients encountered in contemporary surgical practice. J Vasc Surg. 2015;62:392–400.
5.
ArmstrongEJAlamSHenaoS, et al. Multidisciplinary care for critical limb ischemia: current gaps and opportunities for improvement. J Endovasc Ther. 2019;26:199–212.
6.
RudofkerEWHoganSEArmstrongEJ.Preventing major amputations in patients with critical limb ischemia. Curr Cardiol Rep. 2018;20:74.
7.
GoodneyPPBeckAWNagleJ, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50:54–60.
8.
AntoniouGAGeorgiadisGSAntoniouSA, et al. Bypass surgery for chronic lower limb ischaemia. Cochrane Database Syst Rev. 2017;4:CD002000.
9.
GokselOSKarpuzogluEIsseverH, et al. Midterm results with drug-coated balloons for SFA lesions in patients with CLI: comparison with conventional bypass surgery. Int Angiol. 2018;37:365–369.
10.
ReijnenMvan WijckIZellerT, et al. Outcomes after drug-coated balloon treatment of femoropopliteal lesions in patients with critical limb ischemia: a post hoc analysis from the IN.PACT Global study. J Endovasc Ther. 2019;26:305–315.
11.
ArmstrongEJRyanMPBakerER, et al. Risk of major amputation or death among patients with critical limb ischemia initially treated with endovascular intervention, surgical bypass, minor amputation, or conservative management. J Med Econ. 2017;20:1148–1154.
12.
TepeGLairdJSchneiderP, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
13.
Gerhard-HermanMDGornikHLBarrettC, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:1465–1508.
14.
KatsanosKKitrouPSpiliopoulosS, et al. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23:851–863.
15.
SchillingerMSabetiSLoeweC, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. New Engl J Med. 2006;354:1879–1888.
16.
SinghSArmstrongEJSherifW, et al. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med. 2014;19:307–314.
17.
WestinGGArmstrongEJBangH, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63:682–690.
18.
ShammasANJeon-SlaughterHTsaiS, et al. Major limb outcomes following lower extremity endovascular revascularization in patients with and without diabetes mellitus. J Endovasc Ther. 2017;24:376–382.
19.
SchampKBMeerwaldtRReijnenMM, et al. The ongoing battle between infrapopliteal angioplasty and bypass surgery for critical limb ischemia. Ann Vasc Surg. 2012;26:1145–1153.
20.
RosenfieldKJaffMRWhiteCJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
21.
TepeGZellerTAlbrechtT, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg.N Engl J Med. 2008;358:689–699.
22.
DakeMDAnselGMJaffMR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
23.
GiacoppoDCasseseSHaradaY, et al. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016;9:1731–1742.
24.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
25.
SecemskyEAKundiHWeinbergI, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4:332–340.
26.
SchneiderPALairdJRDorosG, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–2563.
MehranRDangasGAbizaidAS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100:1872–1878.
29.
BossiIKlersyCBlackAJ, et al. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. J Am Coll Cardiol. 2000;35:1569–1576.
30.
LiberatiAAltmanDGTetzlaffJ, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
31.
TeymenBAkturkS.Comparison of drug eluting balloon angioplasty to infrapopliteal artery critical lesions with or without additional pedal artery angioplasty in patients with diabetes mellitus and critical limb ischemia. J Interv Cardiol. 2018;31:400–406.
32.
SterneJAHernanMAReevesBC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
33.
HigginsJPAltmanDGGotzschePC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
34.
HigginsJPThompsonSGDeeksJJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
35.
CioppaAStabileEPopusoiG, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: one-year single centre clinical results. Cardiovasc Revasc Med. 2012;13:219–223.
36.
FoleyTRCotterRPKokkinidisDG, et al. Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease. Catheter Cardiovasc Interv. 2017;89:1078–1085.
37.
HsiehCAChouSHChenIC, et al. Feasibility and mid-term outcomes of drug-coated balloon angioplasty between intermittent claudication and critical limb ischemia in patients with femoropopliteal disease. Acta Cardiol Sin. 2019;35:308–319.
38.
LiistroFPortoIAngioliP, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615–621.
39.
PalenaLMDiaz-SandovalLJGomez-JaballeraE, et al. Drug-coated balloon angioplasty for the management of recurring infrapopliteal disease in diabetic patients with critical limb ischemia. Cardiovasc Revasc Med. 2018;19(1pt B):83–87.
40.
PhairJCarnevaleMLipsitzEC, et al. Amputation-free survival in patients with critical limb ischemia treated with paclitaxel-eluting stents and paclitaxel-coated balloons. Ann Vasc Surg. 2020;62:8–14.
41.
SigalaFGalyfosGStavridisK, et al. Prognostic factors in patients treated with drug-coated balloon angioplasty for symptomatic peripheral artery disease. Vasc Specialist Int. 2018;34:94–102.
42.
StabileEGerardiDMagliuloF, et al. One-year clinical outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry. J Endovasc Ther. 2019;26:26–30.
43.
SteinerSSchmidtABausbackY, et al. Single-center experience with Lutonix drug-coated balloons in infrapopliteal arteries. J Endovasc Ther. 2016;23:417–423.
44.
TeichgraberULehmannTThiemeM, et al. drug-coated balloon angioplasty of infrapopliteal lesions in patients with critical limb ischaemia: 1-year results of the APOLLO trial. Cardiovasc Intervent Radiol. 2019;42:1380–1390.
45.
TeymenBAkturkS.Drug-eluting balloon angioplasty for below the knee lesions in end stage renal disease patients with critical limb ischemia: midterm results. J Interv Cardiol. 2017;30:93–100.
46.
TolvaVCasanaRHuibersA, et al. The mid-term clinical follow-up using drug-eluting balloons on tibial artery “de novo” lesions in patients with critical limb ischemia: a cohort study. Vasc Endovascular Surg. 2016;50:304–308.
47.
ZellerTBaumgartnerIScheinertD, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–1576.
48.
HaddadSEShishaniJMQtaishI, et al. One year primary patency of infrapopliteal angioplasty using drug-eluting balloons: single center experience at King Hussein Medical Center. J Clin Imaging Sci. 2017;7:31.
49.
GandiniRDel GiudiceCMerollaS, et al. Treatment of chronic SFA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther. 2013;20:805–814.
50.
RiambauVAcinFde BlasMDrug-coated balloon angioplasty in clinical practice for below the knee, popliteal and crural artery lesions causing critical limb ischaemia: one-year results from the Spanish Luminor Registry. Ann Vasc Surg. 2020;62:387–396.
51.
SchmidtAPiorkowskiMWernerM, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105–1109.
52.
GandiniRDel GiudiceC.Local ultrasound to enhance paclitaxel delivery after femoral-popliteal treatment in critical limb ischemia: the PACUS Trial. JACC Cardiovasc Interv. 2016;9:2147–2153.
53.
LiistroFAngioliPPortoI, et al. Drug-eluting balloon versus drug-eluting stent for complex femoropopliteal arterial lesions: the DRASTICO Study. J Am Coll Cardiol. 2019;74:205–215.
54.
OzpakBBozokSCayirMC.Thirty-six-month outcomes of drug-eluting balloon angioplasty in the infrapopliteal arteries. Vascular. 2018;26:457–463.
55.
RohJWKoYGAhnCM, et al. Risk factors for restenosis after drug-coated balloon angioplasty for complex femoropopliteal arterial occlusive disease. Ann Vasc Surg. 2019;55:45–54.
56.
ScheinertDSchmidtAZellerT, et al. German center subanalysis of the LEVANT 2 global randomized study of the Lutonix drug-coated balloon in the treatment of femoropopliteal occlusive disease. J Endovasc Ther. 2016;23:409–416.
57.
ZellerTBeschornerUPilgerE, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-First in Man study of the Passeo-18 LUX drug releasing BA Balloon Catheter vs. the uncoated Passeo-18 BA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8:1614–1622.
58.
MicariACioppaAVadalaG, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. JACC Cardiovasc Interv. 2012;5:331–338.
59.
WuRTangSWangM, et al. Drug-eluting balloon versus standard percutaneous transluminal angioplasty in infrapopliteal arterial disease: a meta-analysis of randomized trials. Int J Surg. 2016;35:88–94.
60.
ThiemeMLichtenbergMBrodmannM, et al. Lutonix® 014 DCB global below the knee registry study: interim 6-month outcomes. J Cardiovasc Surg (Torino). 2018;59:232–236.
61.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol. 2020;31:202–212.
SchornIMalinoffHAndersonS, et al. The Lutonix® drug-coated balloon: a novel drug delivery technology for the treatment of vascular disease. Adv Drug Deliv Rev. 2017;112:78–87.
64.
ZellerTMicariAScheinertD, et al. The IN.PACT DEEP clinical drug-coated balloon trial: 5-year outcomes. JACC Cardiovasc Interv. 2020;13:431–443.
65.
DeRubertisBGPierceMRyerEJ, et al. Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg. 2008;47:101–108.
66.
TsetisDBelliAM.The role of infrapopliteal angioplasty. Br J Radiol. 2004;77:1007–1015.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
